硫代苹果酸金钠与金诺芬治疗早期类风湿关节炎的对照良好的比较研究

[Well controlled comparative study in early rheumatoid arthritis with gold sodium thiomalate vs. auranofin].

作者信息

Yamamoto S, Mitomo N, Saito T, Nishioka K, Inoue K, Uchida S, Ohata N, Murasawa A, Suzuki A, Mitsui T

机构信息

Matsuyama Red Cross Hospital Center of Rheumatology.

出版信息

Ryumachi. 1990 Feb;30(1):26-44.

PMID:2116042

Abstract

RA Center Liaison Council conducted a comparative study of Auranofin and GST by envelope method on the patients with early RA who experienced the onset of the disease not more than two years ago. In final assessment of overall improvement, 57.9% of Auranofin-administered cases (22/38) showed moderate improvement or above. The comparable figure for GST group was 71.8% (28/39), but there was no statistically significant difference. Adverse reaction ADR incidence for Auranofin group was 12.2% (5/41), while 22.0% for GST (9/41), but the difference was not statistically significant. Drop out due to ADR was observed in 9.8% of Auranofin-administered cases and in 19.5% of GST-administered cases. The results of the study indicate that Auranofin is a most suitable DMARD than GST to be used for early RA, and GST is suitable for more active RA in view of its efficacy. But GST should be administered carefully because of its high ADR incidence.

摘要

类风湿关节炎中心联络委员会采用信封法对疾病发作不超过两年的早期类风湿关节炎患者进行了金诺芬与GST的对比研究。在总体改善情况的最终评估中，接受金诺芬治疗的病例中有57.9%（22/38）显示出中度或以上改善。GST组的可比数字为71.8%（28/39），但无统计学显著差异。金诺芬组的不良反应发生率为12.2%（5/41），而GST组为22.0%（9/41），但差异无统计学意义。因不良反应而退出的情况在接受金诺芬治疗的病例中占9.8%，在接受GST治疗的病例中占19.5%。研究结果表明，对于早期类风湿关节炎，金诺芬比GST更适合作为抗风湿药物使用，而GST鉴于其疗效适用于更活跃的类风湿关节炎。但由于GST不良反应发生率高，应谨慎使用。